Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

The stock's fall snapped a four-day winning streak.

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) ‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports.A number of other ...